Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TENAYA: Faricimab vs Aflibercept in Neovascular Age-related Macular Degeneration
2018-002152-32Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2019
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of faricimab in exudative macular degeneration (2 arms), sponsored by Roche. Primary endpoint: Primary: Change in BCVA from baseline to average at Weeks 40, 44 and 48. Started Mar 2019; status: completed.
02
Drugs
faricimab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2018-002152-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002152-32.